Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nitazoxanide

FDA-approved product (tablet, oral), marketed as Alinia, Nitazoxanide.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitazoxanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Diarrhea

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other agents against amoebiasis and other protozoal diseases
FDA pharmacologic class
Antiprotozoal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX11; FDA class Antiprotozoal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Nitazoxanide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitazoxanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of a Nutritional Support System for Improving Gross Motor Function in Cerebral Palsy

    NCT03933709 · start 2015-01-12

    Registered record
    Registry ID
    NCT03933709
    Conditions
    Nutrition Disorder, Child; Gross Motor Development Delay; Neuro: Cerebral Palsy; Diet Modification; Probiotics
    Interventions
    Nutritional Support System (NSS); deworming; recommended diet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01-12
    Completion
    2017-04-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNutrition Disorder, Child; Gross Motor Development Delay; Neuro: Cerebral Palsy; Diet Modification +1 more
    InterventionNutritional Support System (NSS); deworming; recommended diet
    PhaseNot applicable
    Registry statusCompleted

  • Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori

    NCT02422706 · start 2015-01

    Registered record
    Registry ID
    NCT02422706
    Conditions
    Helicobacter-associated Gastritis
    Interventions
    Nitazoxanide; Metronidazole(MTZ); Omeprazole; Clarithromycin; Levofloxacin; Doxicycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2018-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter-associated Gastritis
    InterventionNitazoxanide; Metronidazole(MTZ); Omeprazole; Clarithromycin +2 more
    PhasePhase 3
    Registry statusUnknown

  • A Two Week Nitazoxanidebased Quadruple Regimen

    NCT02621359 · start 2015-01

    Registered record
    Registry ID
    NCT02621359
    Conditions
    Dyspepsia
    Interventions
    Nitazoxanide; Levofloxacin; Doxycyclin; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2022-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspepsia
    InterventionNitazoxanide; Levofloxacin; Doxycyclin; Omeprazole
    PhasePhase 3
    Registry statusUnknown

  • The Effects of Nitazoxanide in Hepatic Encephalopathy

    NCT02334163 · start 2014-12

    Registered record
    Registry ID
    NCT02334163
    Conditions
    Hepatic Encephalopathy
    Interventions
    Nitazoxanide; Oral lactulose; Metronidazole; Rifaximine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2015-04
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy
    InterventionNitazoxanide; Oral lactulose; Metronidazole; Rifaximine
    PhasePhase 2
    Registry statusUnknown

  • Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

    NCT02366884 · start 2011-07-26

    Registered record
    Registry ID
    NCT02366884
    Conditions
    Neoplasms
    Interventions
    Anti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-07-26
    Completion
    2023-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionAnti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

    NCT01227421 · start 2010-12

    Registered record
    Registry ID
    NCT01227421
    Conditions
    Influenza
    Interventions
    Nitazoxanide; Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2011-05
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza
    InterventionNitazoxanide; Nitazoxanide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

    NCT01276756 · start 2010-12

    Registered record
    Registry ID
    NCT01276756
    Conditions
    Chronic Hepatitis c
    Interventions
    Pegylated interferon alfa-2a; Nitazoxanide; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis c
    InterventionPegylated interferon alfa-2a; Nitazoxanide; Ribavirin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients

    NCT01197157 · start 2010-09

    Registered record
    Registry ID
    NCT01197157
    Conditions
    Hepatitis C
    Interventions
    Placebo; Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2014-04
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionPlacebo; Nitazoxanide
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

    NCT00637923 · start 2008-03

    Registered record
    Registry ID
    NCT00637923
    Conditions
    Chronic Hepatitis C
    Interventions
    Nitazoxanide; Placebo; Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-03
    Completion
    2010-04
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNitazoxanide; Placebo; Peginterferon alfa-2a; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

    NCT00495391 · start 2007-07

    Registered record
    Registry ID
    NCT00495391
    Conditions
    Chronic Hepatitis C
    Interventions
    Nitazoxanide; Placebo; Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2010-02
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNitazoxanide; Placebo; Peginterferon alfa-2a; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

    NCT00384527 · start 2006-12

    Registered record
    Registry ID
    NCT00384527
    Conditions
    Clostridium Infections
    Interventions
    Nitazoxanide; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-12
    Completion
    2007-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClostridium Infections
    InterventionNitazoxanide; Vancomycin
    PhasePhase 3
    Registry statusTerminated

  • 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

    NCT00763568 · start 2006-08

    Registered record
    Registry ID
    NCT00763568
    Conditions
    Chronic Hepatitis C
    Interventions
    Nitazoxanide; Peginterferon alfa-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2008-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNitazoxanide; Peginterferon alfa-2a
    PhasePhase 2
    Registry statusCompleted

  • Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C

    NCT00421434 · start 2006-06

    Registered record
    Registry ID
    NCT00421434
    Conditions
    Chronic Hepatitis C
    Interventions
    Nitazoxanide; Peginterferon alfa-2a; Peginterferon alfa-2a; Ribavirin; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2008-09
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNitazoxanide; Peginterferon alfa-2a; Peginterferon alfa-2a; Ribavirin +1 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children

    NCT01328925 · start 2005-12

    Registered record
    Registry ID
    NCT01328925
    Conditions
    Rotavirus Infection; Viral Gastroenteritis Due to Rotavirus
    Interventions
    Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-12
    Completion
    2006-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRotavirus Infection; Viral Gastroenteritis Due to Rotavirus
    InterventionNitazoxanide
    PhasePhase 2
    Registry statusCompleted

  • Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

    NCT00130390 · start 2005-08

    Registered record
    Registry ID
    NCT00130390
    Conditions
    Crohn's Disease
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2005-08
    Completion
    2008-07
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionNitazoxanide; Placebo
    PhasePhase 2
    Registry statusTerminated